请输入您要查询的百科知识：

　

词条 Intellia Therapeutics
释义

  1. History

  2. References

{{short description|Biotechnology company}}{{Infobox company
| name = Intellia Therapeutics
| logo =
| type = Public
| traded_as = {{unbulleted list|{{NASDAQ|NTLA}}|Russell 2000 Component}}
| foundation = 2014
| location_city = Cambridge, MA
| location_country = United States
| key_people = {{unbulleted list|John Leonard {{small|(President & CEO)}}| Glenn Goddard {{small|(CFO)}}|Thomas Barnes {{small|(SVP)}}}}
| industry = Biotherapeutics
| homepage = {{url|intelliatx.com}}
}}

Intellia Therapeutics is a biotechnology company developing biopharmaceuticals using a CRISPR gene editing system invented by Jennifer Doudna and colleagues at University of California. The company has partnerships with Novartis and Regeneron.

History

Intellia Therapeutics was founded in May 2014 to develop biopharmaceuticals using CRISPR.[1][1]

It was backed by Atlas Venture and Novartis; the founding CEO was Nessan Bermingham from Atlas and the founding CSO was John Leonard, formerly CSO of AbbVie. The academic scientists involved in the founding included Rodolphe Barrangou, Rachel Haurwitz, Luciano Marraffini, Eric Sontheimer, and Derek Rossi.[2] The Series A round investment in November 2014 raised $15 million.[3] The intellectual property around CRISPR was contested from the beginning; Intellia in-licensed patents from Caribou Biosciences, which had licensed patents from University of California invented by Jennifer Doudna.[5][4]

Novartis had funded the Series A round because of its interest in applying CRISPR in CAR-T, and in January 2015 Novartis and Intellia reached a deal through which Novartis obtained rights to use CRISPR for its CAR-T program, and the companies agreed to collaborate on ways to use CRISPR to treat diseases involving hematopoetic stem cells including beta thalassemia] and sickle cell disease.[5] Intellia formed a division called eXtellia Therapeutics to manage the CAR-T collaboration with Novartis.[6]

As of February 2015, Intellia's competitors included CRISPR Therapeutics (with IP invented by Emmanuelle Charpentier) , Editas Medicine (with IP invented by Feng Zhang from the Broad Institute) and Horizon Discovery. Among large pharmaceutical companies, AstraZeneca had the broadest set of collaborations in CRISPR.[7][8]

In September 2015, a Series B round secured $70 million.[9]

In May 2016, Intellia announced the closing of its initial public offering which raised approximately $112.1 million.[10][11] In the course of going public, the company disclosed that it had licensed the lipid drug delivery system from Novartis, and that it involved creating lipid droplets to encapsulate the CRISPR agents.[10]

In April 2017 Intellia entered into a partnership with Regeneron under which Regeneron gained the exclusive right to use Intellia's CRISPR platform on up to 10 drug targets, of which up to five could be outside of the liver, and the companies agreed to co-develop other targets. Regeneron paid $75 million upfront, as well as milestones and royalties.[12] The company said it planned to put $10 million of the funds into its bioinformatics program, to help it evaluate targets.[13]

In December 2016, the company moved to its new 80,000 sq. ft. laboratory and office space in Cambridge, Massachusetts.[14] By that time, it had in-licensed a lipid nanoparticle drug delivery system to help with its efforts to deliver its CRISPR drugs to the liver, without being degraded in the bloodstream; at that time it had not disclosed the licensor.[15]

In March 2017 Intellia and Regeneron, its partner in co-developing a CRISPR-based treatment for transthyretin amyloidosis, presented data from a gene editing experiment in mice.[16][17] By that time, University of California had lost a challenge to Broad's CRISPR patents, putting Intellia at a disadvantage relative to Editas.[16]

In December 2017 Leonard, who had experience in drug development, took over as CEO.[18]

References

1. ^{{cite news| title = Why Gene Editing Has Scientists Excited| newspaper = Wall Street Journal| date = June 28, 2015| url = https://www.wsj.com/articles/why-gene-editing-technology-has-scientists-excited-1434985998}}
2. ^1 {{cite web| title = Novartis joins Atlas in launching a CRISPR Cas biotech with a $15M bankroll| publisher = Fierce Biotech| date = November 18, 2014| url = http://www.fiercebiotech.com/r-d/novartis-joins-atlas-launching-a-crispr-cas-biotech-a-15m-bankroll}}
3. ^{{cite news| title = Intellia Therapeutics Raises $15M Series A for Gene Editing Therapies| newspaper = Wall Street Journal| date = November 18, 2014| url = https://www.wsj.com/articles/DJFVW00120141118eabiausvv}}
4. ^{{cite news |last1=Lash |first1=Alex |title=Xconomy: With Atlas Cash and Berkeley Tools, Intellia Joins the CRISPR Fray |url=https://www.xconomy.com/boston/2014/11/18/with-atlas-cash-and-berkeley-tools-intellia-joins-the-crispr-fray/?single_page=true |work=Xconomy |date=18 November 2014}}
5. ^1 {{cite news| title = Novartis secures first CRISPR pharma collaborations| journal = Xconomy| date = January 7, 2017| url = https://www.xconomy.com/boston/2015/01/07/cart-crispr-1st-of-its-kind-biotech-deal-from-novartis-intellia/?single_page=true/}}
6. ^{{cite news| title = Intellia Therapeutics Forms New Division eXtellia for Joint Programs with Novartis| journal = BIO.IT World| date = January 14, 2016| url = http://www.bio-itworld.com/2016/1/14/intellia-therapeutics-forms-new-division-extellia-joint-programs-novartis.html}}
7. ^{{cite news| title = Gene editing comes of healthcare age| newspaper = Financial Times| date = February 16, 2015| url = https://www.ft.com/content/544f152c-b070-11e4-a2cc-00144feab7de}}
8. ^{{cite journal |last1=Mullard |first1=Asher |title=Novartis secures first CRISPR pharma collaborations |journal=Nature Reviews Drug Discovery |date=1 February 2015 |volume=14 |issue=2 |pages=82–82 |doi=10.1038/nrd4546}}
9. ^{{cite news| title = Intellia raises $70 million for gene-editing treatments| newspaper = Boston Globe| date = September 1, 2015| url = https://www.bostonglobe.com/business/2015/09/01/intellia-raises-million-for-gene-editing-treatments/Er3l8K2EEiWlc7m2aoRQgJ/story.html}}
10. ^1 {{cite web| title = Form 10-K for the Fiscal Year Ended December 31, 2016| publisher = Intellia via SEC Edgar| url = https://www.sec.gov/Archives/edgar/data/1652130/000119312517082186/d284545d10k.htm}}
11. ^{{cite news| title = Stock in Biotech Company Intellia Rises 23% After Upsized IPO| newspaper = Wall Street Journal| date = May 6, 2016| url = https://www.wsj.com/articles/stock-in-biotech-company-intellia-rises-23-after-upsized-ipo-1462568654}}
12. ^{{cite news |title=Regeneron, Intellia Partner to Develop CRISPR/Cas Therapeutics |url=https://www.genengnews.com/gen-news-highlights/regeneron-intellia-partner-to-develop-crispr-cas-therapeutics/81252598/ |work=Genetic Engineering News |date=April 11, 2016}}
13. ^{{cite news |last1=Taylor |first1=Nick Paul |title=Intellia set to invest millions in CRISPR informatics platform after nailing upsized IPO |url=https://www.fiercebiotech.com/it/intellia-set-to-invest-millions-crispr-informatics-platform-after-nailing-upsized-ipo |work=FierceBiotech |date=May 6, 2016 |language=en}}
14. ^{{cite news| title = Exclusive: Fast-growing gene-editing biotech expanding near Kendall Square| journal = Boston Business Journal| date = January 22, 2016| url = http://www.bizjournals.com/boston/real_estate/2016/01/exclusive-fast-growing-gene-editing-biotech.html}}
15. ^{{cite news |last1=Lash |first1=Alex |title=Xconomy: CRISPR Cash: Intellia The Latest Gene-Editing Firm To Nab Big Money |url=https://www.xconomy.com/boston/2015/09/01/crispr-cash-intellia-the-latest-gene-editing-firm-to-nab-big-money/ |work=Xconomy |date=1 September 2015}}
16. ^1 {{cite news |last1=Stendahl |first1=Max |title=Intellia R&D head says new gene-editing data shows path to human trials|url=http://www.bizjournals.com/boston/news/2017/03/08/intellia-r-d-head-says-new-gene-editing-data.html |work=Boston Business Journal |date=March 8, 2017}}
17. ^{{cite news |last1=Le Page |first1=Michael |title=We’re nearly ready to use CRISPR to target far more diseases |url=https://www.newscientist.com/article/2149129-were-nearly-ready-to-use-crispr-to-target-far-more-diseases/ |work=New Scientist |date=October 2, 2017}}
18. ^{{cite news |title=Press release: Intellia Therapeutics Names John Leonard, M.D., President and Chief Executive Officer {{!}} Intellia Therapeutics |url=https://ir.intelliatx.com/news-releases/news-release-details/intellia-therapeutics-names-john-leonard-md-president-and-chief |work=Intellia Therapeutics |date=December 18, 2017 |language=en}}

4 : Pharmaceutical companies of the United States|2014 establishments in the United States|Pharmaceutical companies established in 2014|Companies listed on NASDAQ
随便看

　

开放百科全书收录14589846条英语、德语、日语等多语种百科知识，基本涵盖了大多数领域的百科知识，是一部内容自由、开放的电子版国际百科全书。

　

Copyright © 2023 OENC.NET All Rights Reserved
京ICP备2021023879号 更新时间：2024/11/13 22:43:35